• Author
    Sofi Castanon
  • Discovery PI

    Aaron Lisberg

  • Project Co-Author

    Olga Tsvetkova

  • Abstract Title

    Therapy related toxicity is associated with clinical benefit in advanced lung cancer patients: An Exploratory Analysis.

  • Discovery AOC Petal or Dual Degree Program

    Basic, Clinical, & Translational Research

  • Abstract

    Keywords: Novel Therapies, trAE (treatment-related adverse event), Clinical outcomes, Lung Cancer

    Background: Datopotamab deruxtecan (Dato-DXd) is a novel ADC currently being investigated in various solid tumor types and approved for the treatment of breast and lung cancer. Dato-Dxd is a monoclonal antibody that targets trophoblast cell-surface antigen 2 (Trop2) linked to a topoisomerase I inhibitor payload. To date, Dato-Dxd has shown promising efficacy in both epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and hormone receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). In addition, Dato-DXd has shown a favorable safety profile when compared to standard chemotherapy. However, this ADC is associated with adverse events of special interest (AESI) including mucositis, interstitial lung disease, and ocular surface events. Although these AESIs are generally well-managed with prophylaxis, early intervention, and monitoring, they can adversely affect patient quality of life. Therefore, efforts to understand their role in relation to treatment efficacy can potentially aid clinical decision-making.

    Objective: To evaluate the relationship between trAEs, including AESIs and PFS (progression free survival) in a cohort of lung cancer patients treated with Dato-Dxd.

    Methods: In this retrospective analysis of 43 lung cancer patients treated with Dato-DXd on clinical trials, AEs were classified as trAEs/AESI if they were assessed by the investigator as possibly, probably, or definitely related to treatment with Dato-DXd. Their association with PFS was evaluated using a time-varying Cox model adjusted for dose assigned at cycle 1.

Back